Guardant Health Announces Multi-Year Strategic Collaboration Agreement with MSD to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform

Guardant Health, Inc., a leading precision oncology company, announced a multi-year collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), to support the development and commercialization of MSD’s oncology portfolio using the Guardant Infinity™ Smart platform.